- Home
- ATHE vs MBIO Comparison
ATHE vs MBIO Comparison
Compare ATHE & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHE
- MBIO
- Stock Information
- Founded
- ATHE 1997
- MBIO 2015
- Country
- ATHE Australia
- MBIO United States
- Employees
- ATHE N/A
- MBIO N/A
- Industry
- ATHE Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ATHE Health Care
- MBIO Health Care
- Exchange
- ATHE Nasdaq
- MBIO Nasdaq
- Market Cap
- ATHE 10.1M
- MBIO 9.1M
- IPO Year
- ATHE N/A
- MBIO N/A
- Fundamental
- Price
- ATHE $2.20
- MBIO $0.17
- Analyst Decision
- ATHE Strong Buy
- MBIO Strong Buy
- Analyst Count
- ATHE 2
- MBIO 1
- Target Price
- ATHE $6.00
- MBIO $2.00
- AVG Volume (30 Days)
- ATHE 121.1K
- MBIO 669.7K
- Earning Date
- ATHE 02-15-2025
- MBIO 11-08-2024
- Dividend Yield
- ATHE N/A
- MBIO N/A
- EPS Growth
- ATHE N/A
- MBIO N/A
- EPS
- ATHE N/A
- MBIO N/A
- Revenue
- ATHE $2,681,669.00
- MBIO N/A
- Revenue This Year
- ATHE N/A
- MBIO N/A
- Revenue Next Year
- ATHE N/A
- MBIO N/A
- P/E Ratio
- ATHE N/A
- MBIO N/A
- Revenue Growth
- ATHE 2.63
- MBIO N/A
- 52 Week Low
- ATHE $1.00
- MBIO $0.13
- 52 Week High
- ATHE $3.19
- MBIO $1.53
- Technical
- Relative Strength Index (RSI)
- ATHE 64.85
- MBIO 33.19
- Support Level
- ATHE $2.04
- MBIO $0.15
- Resistance Level
- ATHE $2.45
- MBIO $0.21
- Average True Range (ATR)
- ATHE 0.23
- MBIO 0.02
- MACD
- ATHE -0.00
- MBIO -0.00
- Stochastic Oscillator
- ATHE 71.15
- MBIO 25.56
About ATHE Alterity Therapeutics Limited
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.